Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Details
Publication Year 2023-07,Volume 50,Issue #9,Page 2830-2845
Journal Title
European Journal of Nuclear Medicine and Molecular Imaging
Publication Type
Guideline
Abstract
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [(177)Lu]Lu-PSMA-617 in combination with standard-of-care has been demonstrated in patients with metastatic castration-resistant prostate cancer, whose disease had progressed after or during at least one taxane regimen and at least one novel androgen-axis drug. Preliminary data suggest that (177)Lu-PSMA-radioligand therapy (RLT) also has high potential in additional clinical situations. Hence, the radiopharmaceuticals [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T are currently being evaluated in ongoing phase 3 trials. The purpose of this guideline is to assist nuclear medicine personnel, to select patients with highest potential to benefit from (177)Lu-PSMA-RLT, to perform the procedure in accordance with current best practice, and to prepare for possible side effects and their clinical management. We also provide expert advice, to identify those clinical situations which may justify the off-label use of [(177)Lu]Lu-PSMA-617 or other emerging ligands on an individual patient basis.
Publisher
Springer Nature
Keywords
Male; Humans; Prostate-Specific Antigen; *Prostatic Neoplasms, Castration-Resistant/diagnostic imaging/radiotherapy; Radiopharmaceuticals/adverse effects; *Nuclear Medicine; Heterocyclic Compounds, 1-Ring/therapeutic use; Dipeptides/therapeutic use; Lutetium/therapeutic use; Treatment Outcome; Eanm/snmmi; Psma; [177Lu]Lu-PSMA-617
Department(s)
Cancer Imaging
PubMed ID
37246997
Open Access at Publisher's Site
https://doi.org/10.1007/s00259-023-06255-8
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-09-28 07:45:36
Last Modified: 2023-09-28 07:46:07

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙